1596 related articles for article (PubMed ID: 31332738)
21. Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study.
Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC
J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):561-570. PubMed ID: 34412109
[TBL] [Abstract][Full Text] [Related]
22. Phytocannabinoid Pharmacology: Medicinal Properties of
Sampson PB
J Nat Prod; 2021 Jan; 84(1):142-160. PubMed ID: 33356248
[TBL] [Abstract][Full Text] [Related]
23. Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Relevant to Electronic Cigarette Liquids.
Hindelang P; Scharinger A; Richling E; Walch SG; Lachenmeier DW
Front Biosci (Landmark Ed); 2022 Jul; 27(8):228. PubMed ID: 36042166
[TBL] [Abstract][Full Text] [Related]
24. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
Devinsky O; Cilio MR; Cross H; Fernandez-Ruiz J; French J; Hill C; Katz R; Di Marzo V; Jutras-Aswad D; Notcutt WG; Martinez-Orgado J; Robson PJ; Rohrback BG; Thiele E; Whalley B; Friedman D
Epilepsia; 2014 Jun; 55(6):791-802. PubMed ID: 24854329
[TBL] [Abstract][Full Text] [Related]
25. Cannabis for the Treatment of Epilepsy: an Update.
Gaston TE; Szaflarski JP
Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
[TBL] [Abstract][Full Text] [Related]
26. Cannabis sativa: Much more beyond Δ
Alves P; Amaral C; Teixeira N; Correia-da-Silva G
Pharmacol Res; 2020 Jul; 157():104822. PubMed ID: 32335286
[TBL] [Abstract][Full Text] [Related]
27. Source of cannabinoids: what is available, what is used, and where does it come from?
Specchio N; Pietrafusa N; Cross HJ
Epileptic Disord; 2020 Jan; 22(S1):1-9. PubMed ID: 31941643
[TBL] [Abstract][Full Text] [Related]
28. Heterogeneity in the composition of marijuana seized in California.
Burgdorf JR; Kilmer B; Pacula RL
Drug Alcohol Depend; 2011 Aug; 117(1):59-61. PubMed ID: 21288662
[TBL] [Abstract][Full Text] [Related]
29. Medical use of cannabis. Cannabidiol: a new light for schizophrenia?
Deiana S
Drug Test Anal; 2013 Jan; 5(1):46-51. PubMed ID: 23109356
[TBL] [Abstract][Full Text] [Related]
30.
Canseco-Alba A; Rodríguez-Manzo G
Rev Invest Clin; 2023; 75(3):105-128. PubMed ID: 37441766
[TBL] [Abstract][Full Text] [Related]
31. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.
Hindocha C; Freeman TP; Schafer G; Gardener C; Das RK; Morgan CJ; Curran HV
Eur Neuropsychopharmacol; 2015 Mar; 25(3):325-34. PubMed ID: 25534187
[TBL] [Abstract][Full Text] [Related]
32. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
[TBL] [Abstract][Full Text] [Related]
33. Dark Classics in Chemical Neuroscience: Δ
Banister SD; Arnold JC; Connor M; Glass M; McGregor IS
ACS Chem Neurosci; 2019 May; 10(5):2160-2175. PubMed ID: 30689342
[TBL] [Abstract][Full Text] [Related]
34. The yin and yang of cannabis-induced psychosis: the actions of Δ(9)-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia.
Arnold JC; Boucher AA; Karl T
Curr Pharm Des; 2012; 18(32):5113-30. PubMed ID: 22716133
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.
Rosenberg EC; Patra PH; Whalley BJ
Epilepsy Behav; 2017 May; 70(Pt B):319-327. PubMed ID: 28190698
[TBL] [Abstract][Full Text] [Related]
36. Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy.
Allendorfer JB; Szaflarski JP
Epilepsy Behav; 2017 May; 70(Pt B):349-354. PubMed ID: 28109780
[TBL] [Abstract][Full Text] [Related]
37. Individual and combined effects of cannabidiol and Δ
Wall MB; Freeman TP; Hindocha C; Demetriou L; Ertl N; Freeman AM; Jones AP; Lawn W; Pope R; Mokrysz C; Solomons D; Statton B; Walker HR; Yamamori Y; Yang Z; Yim JL; Nutt DJ; Howes OD; Curran HV; Bloomfield MA
J Psychopharmacol; 2022 Jun; 36(6):732-744. PubMed ID: 35596578
[TBL] [Abstract][Full Text] [Related]
38. Neuroprotective Effects of Cannabidiol but Not Δ
Landucci E; Mazzantini C; Lana D; Davolio PL; Giovannini MG; Pellegrini-Giampietro DE
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575932
[TBL] [Abstract][Full Text] [Related]
39. Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses.
Walsh KB; McKinney AE; Holmes AE
Front Pharmacol; 2021; 12():777804. PubMed ID: 34916950
[TBL] [Abstract][Full Text] [Related]
40. The Pharmacological Basis of Cannabis Therapy for Epilepsy.
Reddy DS; Golub VM
J Pharmacol Exp Ther; 2016 Apr; 357(1):45-55. PubMed ID: 26787773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
